Hims & Hers Drops 16% Amid Novo Nordisk Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy HIMS?
Source: Yahoo Finance
- Significant Stock Decline: Hims & Hers Health closed at $19.33 on Monday, down 16.03%, reflecting market concerns over legal risks, particularly following the lawsuit filed by Novo Nordisk.
- Surge in Trading Volume: The company experienced a trading volume of 143.5 million shares, which is 688% above its three-month average of 18.2 million shares, indicating heightened investor anxiety regarding its future.
- Increased Legal Pressure: The lawsuit from Novo Nordisk seeks to prevent Hims & Hers from selling compounded versions of its patented drugs, intensifying the legal and regulatory challenges the company faces, which could impact its market strategy.
- Negative Market Reaction: Hims & Hers has seen a cumulative decline of 26.89% over the past five days, suggesting a waning investor confidence in its business transformation, especially after the announcement to withdraw its copycat obesity drug Wegovy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 28.150
Low
16.50
Averages
32.95
High
60.00
Current: 28.150
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Mostly Higher, Intel Hits Record High
- Intel Stock Surge: Intel (INTC) shares rose over 22% to a record high after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding expectations of $13.04 billion, thereby boosting overall confidence in the semiconductor sector and reflecting optimism about the economic potential of artificial intelligence.
- Consumer Confidence Rebound: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing expectations of 48.5, indicating an increase in consumer confidence which could stimulate spending and drive economic growth.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell over 1% amid expectations of renewed US-Iran talks, potentially exacerbating the global energy crisis and affecting operational costs and profit forecasts for energy-intensive sectors.
- Strong Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb 12% year-over-year, demonstrating resilience in corporate profitability that may further boost market sentiment.
See More
Midday Market Moves: Notable Stock Fluctuations
- Comcast Downgrade: Comcast's stock fell nearly 8% after Deutsche Bank downgraded its rating from Buy to Hold, with analysts indicating that while there is visibility into sustainable revenue and EBITDA growth, they do not expect multiple expansion, highlighting challenges in a stable but non-growing business environment.
- HCA Healthcare Decline: HCA Healthcare's stock dropped over 7% due to a milder flu season resulting in fewer patient admissions, and although the company narrowly beat analyst profit estimates, investors are concerned about declining patient demand as Affordable Care Act subsidies phase out.
- Organon Surge: Organon's stock spiked 22% following a report from The Economic Times that Sun Pharma plans to submit a $13 billion offer for the U.S.-based company, which could significantly enhance Organon's market value and investor confidence.
- Intel Earnings Beat: Intel reported first-quarter earnings of 29 cents per share on revenue of $13.58 billion, both exceeding Wall Street expectations, leading to a stock rally of over 23%, indicating a strong recovery momentum in the semiconductor market that may boost overall industry investment enthusiasm.
See More
Mixed US Stocks with Intel Surging 22% on Strong Q2 Forecast
- Intel's Strong Outlook: Intel forecasts Q2 revenue between $13.8 billion and $14.8 billion, exceeding expectations of $13.04 billion, leading to a 22% stock surge that reignites optimism in the semiconductor sector, potentially driving increased investments and R&D across the industry.
- Market Optimism: The stock market is mostly higher as talks between the US and Iran appear to be resuming, with the Nasdaq 100 reaching an all-time high, reflecting investor expectations for reduced geopolitical risks, which may enhance market stability and investor confidence.
- WTI Oil Price Fluctuations: WTI crude oil prices fell over 1% after initially gaining 1% due to the US naval blockade on Iran, which could exacerbate the global energy crisis, impacting oil prices and the profitability of related companies, particularly in the Middle East.
- Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to rise 12% year-over-year, indicating improved corporate profitability that may further drive stock market gains and bolster investor confidence.
See More
Hims & Hers Health Shares Rise After J.P. Morgan Overweight Rating
- Rating Upgrade: J.P. Morgan initiated coverage on Hims & Hers Health (HIMS) with an Overweight rating and a December 2026 price target of $35, indicating strong confidence in the telehealth platform and likely attracting more investor interest.
- Strategic Partnership: Analyst Cory Carpenter highlighted that the recent partnership with Novo Nordisk (NVO) could be a turning point for Hims, especially as GLP-1 sales, which account for over 35% of its business, faced uncertainty, alleviating legal risks and enhancing market competitiveness.
- Market Expansion Potential: The FDA's recent decision to loosen restrictions on 12 peptides for mass compounding could expand Hims' total addressable market, with significant revenue growth anticipated in 2027 as a result of this policy change.
- Future Growth Drivers: The combination of a more stable GLP-1 business, peptide legalization, revenue acceleration in the second half, and the potential for more branded partnerships over time creates a compelling catalyst path that could attract skeptical investors.
See More
Key Wall Street Rating Changes Overview
- Intel Upgrade: Evercore ISI upgraded Intel from 'In Line' to 'Outperform', citing improved execution under the new CEO, who has fixed the balance sheet and put the company back on a competitive track, which is expected to drive stock price appreciation.
- Maxlinear Upgrade: Needham upgraded Maxlinear from 'Hold' to 'Buy' after the company reported a Q1 beat and guided Q2 well above Street expectations, indicating strong demand driven by data center growth, which could enhance future revenue.
- Shake Shack Initiation: Guggenheim initiated coverage on Shake Shack with a 'Buy' rating and a $120 price target, anticipating profit growth for the burger chain, reflecting positive market sentiment regarding its future performance.
- Oracle Initiation: Wedbush initiated coverage on Oracle with an 'Outperform' rating and a $225 price target, arguing that the market is fundamentally misinterpreting the company's aggressive investment cycle as speculative risk, which could lead to stock price increases.
See More
Hims & Hers' Partnership with Novo Nordisk Seen as a Turning Point
- Positive Partnership Outlook: Hims & Hers' collaboration with Novo Nordisk is viewed by JPMorgan as a 'turning point' that not only alleviates key legal concerns but also lays the groundwork for the company's expansion in the GLP-1 weight-loss product sector.
- Market Response: Following a bullish report from JPMorgan, Hims & Hers' shares rose about 4% in pre-market trading on Friday, reflecting market optimism regarding its GLP-1 product line expansion, despite a decline of over 9% in the stock price on Thursday for the third consecutive day.
- Growth Potential: Analysts highlight that Hims & Hers has built a leading direct-to-consumer healthcare platform serving approximately 2.5 million subscribers across various sectors, and it is poised for revenue rebound through further branded partnerships.
- Intensifying Competition: Despite progress in the GLP-1 market, Hims & Hers faces challenges from competitors like Amazon and Ro, which are lowering prices and expanding services to capture market share, potentially impacting Hims & Hers' market position.
See More
US Stocks Mostly Higher, Intel Hits Record High
- Intel Stock Surge: Intel (INTC) shares rose over 22% to a record high after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding expectations of $13.04 billion, thereby boosting overall confidence in the semiconductor sector and reflecting optimism about the economic potential of artificial intelligence.
- Consumer Confidence Rebound: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing expectations of 48.5, indicating an increase in consumer confidence which could stimulate spending and drive economic growth.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell over 1% amid expectations of renewed US-Iran talks, potentially exacerbating the global energy crisis and affecting operational costs and profit forecasts for energy-intensive sectors.
- Strong Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb 12% year-over-year, demonstrating resilience in corporate profitability that may further boost market sentiment.
See More
Midday Market Moves: Notable Stock Fluctuations
- Comcast Downgrade: Comcast's stock fell nearly 8% after Deutsche Bank downgraded its rating from Buy to Hold, with analysts indicating that while there is visibility into sustainable revenue and EBITDA growth, they do not expect multiple expansion, highlighting challenges in a stable but non-growing business environment.
- HCA Healthcare Decline: HCA Healthcare's stock dropped over 7% due to a milder flu season resulting in fewer patient admissions, and although the company narrowly beat analyst profit estimates, investors are concerned about declining patient demand as Affordable Care Act subsidies phase out.
- Organon Surge: Organon's stock spiked 22% following a report from The Economic Times that Sun Pharma plans to submit a $13 billion offer for the U.S.-based company, which could significantly enhance Organon's market value and investor confidence.
- Intel Earnings Beat: Intel reported first-quarter earnings of 29 cents per share on revenue of $13.58 billion, both exceeding Wall Street expectations, leading to a stock rally of over 23%, indicating a strong recovery momentum in the semiconductor market that may boost overall industry investment enthusiasm.
See More
Mixed US Stocks with Intel Surging 22% on Strong Q2 Forecast
- Intel's Strong Outlook: Intel forecasts Q2 revenue between $13.8 billion and $14.8 billion, exceeding expectations of $13.04 billion, leading to a 22% stock surge that reignites optimism in the semiconductor sector, potentially driving increased investments and R&D across the industry.
- Market Optimism: The stock market is mostly higher as talks between the US and Iran appear to be resuming, with the Nasdaq 100 reaching an all-time high, reflecting investor expectations for reduced geopolitical risks, which may enhance market stability and investor confidence.
- WTI Oil Price Fluctuations: WTI crude oil prices fell over 1% after initially gaining 1% due to the US naval blockade on Iran, which could exacerbate the global energy crisis, impacting oil prices and the profitability of related companies, particularly in the Middle East.
- Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to rise 12% year-over-year, indicating improved corporate profitability that may further drive stock market gains and bolster investor confidence.
See More
Hims & Hers Health Shares Rise After J.P. Morgan Overweight Rating
- Rating Upgrade: J.P. Morgan initiated coverage on Hims & Hers Health (HIMS) with an Overweight rating and a December 2026 price target of $35, indicating strong confidence in the telehealth platform and likely attracting more investor interest.
- Strategic Partnership: Analyst Cory Carpenter highlighted that the recent partnership with Novo Nordisk (NVO) could be a turning point for Hims, especially as GLP-1 sales, which account for over 35% of its business, faced uncertainty, alleviating legal risks and enhancing market competitiveness.
- Market Expansion Potential: The FDA's recent decision to loosen restrictions on 12 peptides for mass compounding could expand Hims' total addressable market, with significant revenue growth anticipated in 2027 as a result of this policy change.
- Future Growth Drivers: The combination of a more stable GLP-1 business, peptide legalization, revenue acceleration in the second half, and the potential for more branded partnerships over time creates a compelling catalyst path that could attract skeptical investors.
See More
Key Wall Street Rating Changes Overview
- Intel Upgrade: Evercore ISI upgraded Intel from 'In Line' to 'Outperform', citing improved execution under the new CEO, who has fixed the balance sheet and put the company back on a competitive track, which is expected to drive stock price appreciation.
- Maxlinear Upgrade: Needham upgraded Maxlinear from 'Hold' to 'Buy' after the company reported a Q1 beat and guided Q2 well above Street expectations, indicating strong demand driven by data center growth, which could enhance future revenue.
- Shake Shack Initiation: Guggenheim initiated coverage on Shake Shack with a 'Buy' rating and a $120 price target, anticipating profit growth for the burger chain, reflecting positive market sentiment regarding its future performance.
- Oracle Initiation: Wedbush initiated coverage on Oracle with an 'Outperform' rating and a $225 price target, arguing that the market is fundamentally misinterpreting the company's aggressive investment cycle as speculative risk, which could lead to stock price increases.
See More
Hims & Hers' Partnership with Novo Nordisk Seen as a Turning Point
- Positive Partnership Outlook: Hims & Hers' collaboration with Novo Nordisk is viewed by JPMorgan as a 'turning point' that not only alleviates key legal concerns but also lays the groundwork for the company's expansion in the GLP-1 weight-loss product sector.
- Market Response: Following a bullish report from JPMorgan, Hims & Hers' shares rose about 4% in pre-market trading on Friday, reflecting market optimism regarding its GLP-1 product line expansion, despite a decline of over 9% in the stock price on Thursday for the third consecutive day.
- Growth Potential: Analysts highlight that Hims & Hers has built a leading direct-to-consumer healthcare platform serving approximately 2.5 million subscribers across various sectors, and it is poised for revenue rebound through further branded partnerships.
- Intensifying Competition: Despite progress in the GLP-1 market, Hims & Hers faces challenges from competitors like Amazon and Ro, which are lowering prices and expanding services to capture market share, potentially impacting Hims & Hers' market position.
See More
